ZA200505543B - Lymphotoxin beta receptor agents in combination with chemotherapeutic agents - Google Patents

Lymphotoxin beta receptor agents in combination with chemotherapeutic agents

Info

Publication number
ZA200505543B
ZA200505543B ZA200505543A ZA200505543A ZA200505543B ZA 200505543 B ZA200505543 B ZA 200505543B ZA 200505543 A ZA200505543 A ZA 200505543A ZA 200505543 A ZA200505543 A ZA 200505543A ZA 200505543 B ZA200505543 B ZA 200505543B
Authority
ZA
South Africa
Prior art keywords
agents
combination
beta receptor
lymphotoxin beta
chemotherapeutic agents
Prior art date
Application number
ZA200505543A
Other languages
English (en)
Inventor
Lepage Doreen
Gill Alan
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of ZA200505543B publication Critical patent/ZA200505543B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA200505543A 2002-12-20 2005-07-08 Lymphotoxin beta receptor agents in combination with chemotherapeutic agents ZA200505543B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43518502P 2002-12-20 2002-12-20

Publications (1)

Publication Number Publication Date
ZA200505543B true ZA200505543B (en) 2006-12-27

Family

ID=32682180

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200505543A ZA200505543B (en) 2002-12-20 2005-07-08 Lymphotoxin beta receptor agents in combination with chemotherapeutic agents

Country Status (16)

Country Link
US (1) US20060134102A1 (no)
EP (1) EP1585547A4 (no)
JP (1) JP2006513225A (no)
KR (1) KR20050094819A (no)
CN (1) CN1753692A (no)
AU (1) AU2003303339A1 (no)
BR (1) BR0317573A (no)
CA (1) CA2509495A1 (no)
EA (1) EA200501019A1 (no)
IS (1) IS7900A (no)
MX (1) MXPA05006663A (no)
NO (1) NO20053529L (no)
PL (1) PL377611A1 (no)
RS (1) RS20050481A (no)
WO (1) WO2004058183A2 (no)
ZA (1) ZA200505543B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
AU1174702A (en) * 2000-10-13 2002-04-22 Biogen Inc Humanized anti-lt-beta-r antibodies
WO2004002431A2 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoyin beta receptor antibodies
WO2004003144A2 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
CN100473664C (zh) * 2002-12-20 2009-04-01 拜奥根Idec马萨诸塞公司 多价淋巴毒素β受体激动剂及其治疗用途
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
JP2007530588A (ja) * 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド レセプターカップリング剤およびその治療用途
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US7812135B2 (en) 2005-03-25 2010-10-12 Tolerrx, Inc. GITR-binding antibodies
WO2006125632A2 (en) * 2005-05-24 2006-11-30 Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
CA2655411A1 (en) * 2006-06-15 2007-12-21 Biogen Idec Ma Inc. Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents
JP5298021B2 (ja) 2006-10-12 2013-09-25 ジェネンテック， インコーポレイテッド リンホトキシン−αに対する抗体
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CN101653599A (zh) * 2006-10-20 2010-02-24 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
CA2693677C (en) 2007-07-12 2018-02-13 Tolerx, Inc. Combination therapies employing gitr binding molecules
IL258931B (en) * 2015-10-06 2022-09-01 Univ Minnesota Medicinal compounds and methods
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
US20210253723A1 (en) * 2018-06-15 2021-08-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
KR102232659B1 (ko) * 2018-07-16 2021-03-26 전북대학교 산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도
CN115087670A (zh) * 2019-12-11 2022-09-20 西拉格国际有限责任公司 包含ltbr和edb结合结构域的多特异性结合分子及其用途
CN117327174A (zh) * 2022-06-24 2024-01-02 广东菲鹏制药股份有限公司 抗新型冠状病毒人源化多价结合蛋白及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CN1146442C (zh) * 1995-01-26 2004-04-21 拜奥根有限公司 作为抗肿瘤剂的淋巴毒素-α/β复合体和抗淋巴毒素-β受体抗体
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
DE69736244T2 (de) * 1996-10-25 2007-05-31 Biogen Idec Ma Inc., Cambridge Lösliche lymphotoxin-beta rezeptoren, anti-lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
AU1174702A (en) * 2000-10-13 2002-04-22 Biogen Inc Humanized anti-lt-beta-r antibodies
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
WO2004002431A2 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoyin beta receptor antibodies
CN100473664C (zh) * 2002-12-20 2009-04-01 拜奥根Idec马萨诸塞公司 多价淋巴毒素β受体激动剂及其治疗用途
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
JP2007530588A (ja) * 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド レセプターカップリング剤およびその治療用途

Also Published As

Publication number Publication date
RS20050481A (en) 2007-08-03
AU2003303339A1 (en) 2004-07-22
CA2509495A1 (en) 2004-07-15
EA200501019A1 (ru) 2006-06-30
MXPA05006663A (es) 2005-09-30
NO20053529L (no) 2005-09-20
CN1753692A (zh) 2006-03-29
EP1585547A2 (en) 2005-10-19
US20060134102A1 (en) 2006-06-22
WO2004058183A3 (en) 2004-12-09
PL377611A1 (pl) 2006-02-06
NO20053529D0 (no) 2005-07-19
EP1585547A4 (en) 2006-10-25
BR0317573A (pt) 2005-11-22
KR20050094819A (ko) 2005-09-28
IS7900A (is) 2005-06-20
WO2004058183A2 (en) 2004-07-15
JP2006513225A (ja) 2006-04-20

Similar Documents

Publication Publication Date Title
ZA200505543B (en) Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
IL197774A0 (en) Corticotropin releasing factor 2 receptor agonists
GB2400312B (en) Back support structure
AU2003275135A8 (en) Pouch with spout
GB0401363D0 (en) Hinge unit and hinge structure using the same
EP1552981A4 (en) SEAT STRUCTURE
EP1908779A4 (en) THYMOSINE BETA-4 DERIVATIVES AND USE THEREOF
IL173746A0 (en) Modified il-4 mutein receptor antagonists
GB2396016B (en) J-spectroscopy in the wellbore
PL368410A1 (en) Polyolefin composition with improved abrasion resistance
AU2003275436A8 (en) Recliner mechanism
EP1501722A4 (en) IMPROVEMENTS IN THE BEAUPRES
GB2388905B (en) Improvements in flow metering
GB0214954D0 (en) Improvements in feeding mechanisms
ZA200404994B (en) Corticotropin releasing factor 2 receptor agonists
GB0215389D0 (en) Receptor
AU2003270247A8 (en) Echo-suppression with short delay
SI1465923T1 (sl) Agonisti receptorja 2 faktorja sproščanja kortikotropina
GB0209507D0 (en) Nuclear receptor structure
GB2405941B (en) J-spectroscopy in the wellbore
GB0211204D0 (en) Receptor and its ligand
TW515457U (en) Fixing seat used in drainpipe
GB0211205D0 (en) Receptor and ligand
TW515247U (en) Zipper with dual rails
AU2003285989A1 (en) Mutations in gaba-b receptor 1 associated with epilepsy